STADA Arzneimittel (SAZ) Given a €74.40 Price Target by Warburg Research Analysts
A number of other brokerages also recently commented on SAZ. Nord/LB set a €74.40 ($88.57) target price on STADA Arzneimittel and gave the stock a sell rating in a research note on Wednesday, November 29th. S&P Global set a €74.40 ($88.57) price target on STADA Arzneimittel and gave the stock a sell rating in a research report on Friday, November 10th. Independent Research set a €82.00 ($97.62) price target on STADA Arzneimittel and gave the stock a neutral rating in a research report on Friday, November 10th. Finally, Commerzbank set a €66.25 ($78.87) price target on STADA Arzneimittel and gave the stock a sell rating in a research report on Tuesday, August 22nd. Four analysts have rated the stock with a sell rating and two have issued a hold rating to the stock. STADA Arzneimittel currently has an average rating of Sell and a consensus price target of €74.08 ($88.18).
Shares of STADA Arzneimittel (ETR SAZ) opened at €87.76 ($104.48) on Wednesday. STADA Arzneimittel has a 12-month low of €46.31 ($55.13) and a 12-month high of €89.50 ($106.55).
About STADA Arzneimittel
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.